Prelude Therapeutics (PRLD) Net Cash Flow Growth (1y) (2020 - 2026)
Prelude Therapeutics (PRLD) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - | - |
| 10 | Prelude Therapeutics | 331.32 Mn | 186.72 Mn | - | -148.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -148.57% |
| Dec 31, 2025 | -1,016.12% |
| Sep 30, 2025 | 225.62% |
| Jun 30, 2025 | -565.14% |
| Mar 31, 2025 | 4,859.42% |
| Dec 31, 2024 | -85.74% |
| Sep 30, 2024 | -58.24% |
| Jun 30, 2024 | -62.15% |
| Mar 31, 2024 | 95.29% |
| Dec 31, 2023 | 143.87% |
| Sep 30, 2023 | -901.67% |
| Jun 30, 2023 | 988.47% |
| Mar 31, 2023 | -162.63% |
| Dec 31, 2022 | 16.18% |
| Sep 30, 2022 | 100.47% |
| Jun 30, 2022 | 95.33% |
| Mar 31, 2022 | -86.31% |
| Dec 31, 2021 | -55.02% |
| Sep 30, 2021 | -237.36% |
| Jun 30, 2021 | -120.57% |